Intelligent One AIUrology Guide
← All chapters Appendix — Abbreviations, Values, and Quick Facts DidacticsPathwaySuggest

Appendix · Central Ohio Urology Group · Ohio

Abbreviations, Values, and Quick Facts

A. Common abbreviations Abbr.

34 pathway steps4 pathways11 local-policy steps
Your learning progress0 of 31 chapters complete

Saved privately in this browser and shared across state tabs.

Didactics

Shared across all locations

A. Common abbreviations

Abbr.

Meaning

Abbr.

Meaning

LUTS

Lower urinary tract symptoms

BPH

Benign prostatic hyperplasia

OAB

Overactive bladder

SUI

Stress urinary incontinence

PVR

Post-void residual

IPSS

Intl. Prostate Symptom Score

AUR

Acute urinary retention

TWOC

Trial without catheter

UroLift

Prostatic urethral lift

PAE

Prostatic artery embolization

InterStim

Sacral neuromodulation (Medtronic)

PNE

Peripheral nerve evaluation

TURP / ThuLEP

TUR of prostate / thulium enucleation

5-ARI

5-alpha-reductase inhibitor

TURBT

TUR of bladder tumor

NMIBC / MIBC

Non-muscle / muscle-invasive bladder ca

BCG

Bacillus Calmette-Guérin

CIS

Carcinoma in situ

UTUC

Upper-tract urothelial carcinoma

RCC / ccRCC

Renal cell carcinoma / clear-cell RCC

SWL / URS / PCNL

Stone procedures

MET

Medical expulsive therapy

ADT

Androgen deprivation therapy

ARPI

Androgen-receptor pathway inhibitor

mCSPC / mCRPC

Metastatic castration-sensitive / -resistant

nmCRPC

Non-metastatic CRPC

BCR

Biochemical recurrence

HRR

Homologous recombination repair

PARP

Poly-ADP-ribose polymerase (inhibitor)

PSMA

Prostate-specific membrane antigen

Lu-177

Lutetium-177 (Pluvicto)

FDG

Fluorodeoxyglucose (PET tracer)

MSI / dMMR

Microsatellite instability / MMR-deficient

SRE

Skeletal-related event

irAE

Immune-related adverse event

MHT

Menopausal hormone therapy

GSM

Genitourinary syndrome of menopause

DEXA

Bone density scan

ONJ

Osteonecrosis of the jaw

GLP-1

Glucagon-like peptide-1 (agonist)

CIC

Clean intermittent catheterization

IC/BPS

Interstitial cystitis / bladder pain syndrome

rUTI

Recurrent urinary tract infection

Estrace

Vaginal estradiol cream

DSD

Detrusor-sphincter dyssynergia

UDS

Urodynamics

DLPP

Detrusor leak point pressure

CP/CPPS

Chronic prostatitis / chronic pelvic pain syndrome

AD

Autonomic dysreflexia

DRE

Digital rectal exam

B. Handy reference values

Item

Rough reference (verify locally)

Microhematuria threshold

≥ 3 RBCs/HPF on microscopy (confirm — do not rely on the dipstick)

Normal PVR

Generally < ~50–100 mL; persistently > 300 mL is significant retention

Stone spontaneous passage

≤ 5 mm: ~70–80%; 5–10 mm: ~40–50%; > 10 mm: unlikely

Torsion salvage window

Near 100% < 6 h; ~70% at 6–12 h; ~20% at 12–24 h

Ischemic priapism

Emergency if > 4 hours

Catheter sizing (adult)

14–18 Fr routine; 20–24 Fr (3-way) for irrigation/clots. Balloon: sterile water, 10 mL

5-ARI effect on PSA

≈ 50% reduction after 6–12 months (double the value to interpret)

IPSS bands

Mild 0–7, Moderate 8–19, Severe 20–35

Normal Qmax (uroflow)

> 15 mL/s (needs a voided volume > 150 mL to be valid)

Dangerous storage pressure

Detrusor leak point pressure > 40 cm H2O → upper-tract risk

Castrate testosterone

< 50 ng/dL (goal on ADT; many target < 20)

Low testosterone threshold

Total T < ~300 ng/dL on TWO early-morning draws, plus symptoms

Testosterone therapy — hold for

Hematocrit > ~54%

BPH procedure by size (our practice)

UroLift < 50 g; PAE > 50 g. PCNL for stones > 4 cm

Semaglutide (Wegovy) titration

0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg weekly, ~4 weeks per step

Denosumab dosing (our practice: biosimilar)

Every ADT patient: baseline DEXA + 60 mg SC q6 months. Every bone-mets patient: baseline DEXA + 120 mg SC every 12 weeks instead. All need dental clearance, calcium and vitamin D levels, and OTC calcium citrate + vitamin D3 gummies providing 1,200 mg calcium daily

Recurrent UTI (our practice protocol)

Hiprex 1 g BID (+ vitamin C 500 mg); vaginal estrogen (Estrace); reduced sugar; daily CIC irrigation with ~300 cc sterile/distilled water

Antibiotic prophylaxis timing

Within 60 minutes of incision; a single pre-op dose for most cases

C. Central Ohio Urology Group positions referenced in this guide

D. Guideline & evidence touchpoints

Important disclaimer

This guide is an educational quick reference for orientation and study, tailored to Central Ohio Urology Group's practice preferences. It is not a substitute for clinical judgment, direct supervision, institutional protocols, or the full text of current guidelines. Drug doses, hold times, and treatment algorithms — especially in oncology, anticoagulation, and weight management — must be verified against up-to-date sources and the treating physician's plan before use. Guidelines and approvals evolve; confirm the latest AUA/SUFU/NCCN/FDA recommendations. Procedural descriptions are a supplement to supervised hands-on training, never a substitute for it.

Clinical Pathway

Click any node to expand

The appendix is reference content, so this pathway is built as a lookup aid: work the track that matches what you are trying to find — decode an abbreviation, check a threshold, confirm what this practice actually does, or find the guideline behind a recommendation. Everything here is a quick reference, not a substitute for the chapter it came from.

Grouped the way they appear in clinic — find the domain first, then the abbreviation.

Decode an abbreviationGrouped the way they appear in clinic — find the domain first, then the abbreviation. STEP 1 · ORIENTIdentify which domain theabbreviation came fromDomain first, then scan the list. STEP 2 · VOIDING & BPHVoiding, BPH, and retentionabbreviationsThe ones you will hear most in a generalclinic day. STEP 3 · BLADDER & UPPER TRACTBladder cancer and upper-tractabbreviationsStaging shorthand and the intravesicalvocabulary. STEP 4 · STONESStone abbreviationsTwo entries that cover most stoneconversations. STEP 5 · ADVANCED PROSTATE CANCERAdvanced prostate cancer andmolecular abbreviationsThe disease-state shorthand used inChapter 20. STEP 6 · IMAGING & ONCOLOGYImaging, theranostics, andoncology-toxicity abbreviationsPET tracers and the complicationshorthand. STEP 7 · WOMEN'S, BONE, METABOLICWomen's health, bone, andmetabolic abbreviationsChapters 22–24 vocabulary. STEP 8 · NEURO-UROLOGY & PAINNeuro-urology, urodynamics, andpelvic pain abbreviationsChapters 25 and 27 vocabulary — plus theone we deliberately do not use.

Select a box to open its teaching details.

Domains in this list

  • Voiding, BPH, and retention
  • Bladder cancer and intravesical therapy
  • Stones
  • Prostate cancer — advanced and molecular
  • Imaging and oncology response
  • Women's health, bone, and metabolic
  • Neuro-urology and pelvic pain

Pitfalls

  • The near-identical pairs in this list carry opposite meanings — NMIBC vs MIBC, mCSPC vs mCRPC vs nmCRPC. Read the whole string before acting on it
  • An abbreviation is a pointer, not a plan — go back to the chapter it came from before you use it clinically
Appendix A — common abbreviations

Symptoms and measures

  • LUTS — lower urinary tract symptoms
  • OAB — overactive bladder
  • SUI — stress urinary incontinence
  • PVR — post-void residual
  • IPSS — International Prostate Symptom Score
  • AUR — acute urinary retention
  • TWOC — trial without catheter

BPH and procedures

  • BPH — benign prostatic hyperplasia
  • UroLift — prostatic urethral lift
  • PAE — prostatic artery embolization
  • TURP / ThuLEP — TUR of prostate / thulium enucleation
  • 5-ARI — 5-alpha-reductase inhibitor

Neuromodulation

  • InterStim — sacral neuromodulation (Medtronic)
  • PNE — peripheral nerve evaluation
Appendix A — common abbreviations

Abbreviations

  • TURBT — TUR of bladder tumor
  • NMIBC / MIBC — non-muscle-invasive / muscle-invasive bladder cancer
  • BCG — Bacillus Calmette-Guérin
  • CIS — carcinoma in situ
  • UTUC — upper-tract urothelial carcinoma
  • RCC / ccRCC — renal cell carcinoma / clear-cell RCC
Appendix A — common abbreviations

Abbreviations

  • SWL / URS / PCNL — stone procedures
  • MET — medical expulsive therapy
Appendix A — common abbreviations

Disease states and therapy

  • ADT — androgen deprivation therapy
  • ARPI — androgen-receptor pathway inhibitor
  • mCSPC / mCRPC — metastatic castration-sensitive / castration-resistant prostate cancer
  • nmCRPC — non-metastatic CRPC
  • BCR — biochemical recurrence

Molecular and targeted

  • HRR — homologous recombination repair
  • PARP — poly-ADP-ribose polymerase (inhibitor)
  • MSI / dMMR — microsatellite instability / mismatch-repair deficient
Appendix A — common abbreviations

Abbreviations

  • PSMA — prostate-specific membrane antigen
  • Lu-177 — lutetium-177 (Pluvicto)
  • FDG — fluorodeoxyglucose (PET tracer)
  • SRE — skeletal-related event
  • irAE — immune-related adverse event
Appendix A — common abbreviations

Abbreviations

  • MHT — menopausal hormone therapy
  • GSM — genitourinary syndrome of menopause
  • Estrace — vaginal estradiol cream
  • DEXA — bone density scan
  • ONJ — osteonecrosis of the jaw
  • GLP-1 — glucagon-like peptide-1 (agonist)
Appendix A — common abbreviations

Abbreviations

  • CIC — clean intermittent catheterization
  • DSD — detrusor-sphincter dyssynergia
  • UDS — urodynamics
  • DLPP — detrusor leak point pressure
  • AD — autonomic dysreflexia
  • IC/BPS — interstitial cystitis / bladder pain syndrome
  • CP/CPPS — chronic prostatitis / chronic pelvic pain syndrome
  • rUTI — recurrent urinary tract infection
  • DRE — digital rectal exam

Note

  • DRE appears in the list, but we do not use the DRE to evaluate for prostate cancer — see the practice-positions track
Appendix A — common abbreviations

Reference values sequenced by the question you are actually asking. All are rough — verify locally.

Check a numberReference values sequenced by the question you are actually asking. All are rough — verify locally. STEP 1 · CAVEATTreat every number here as a roughreference to verify locallyThese are for orientation, notauthority. STEP 2 · IS THIS HEMATURIA?Microhematuria threshold — and donot rely on the dipstickThe threshold is microscopic, notchemical. STEP 3 · IS HE RETAINING?Normal PVR and thesignificant-retention thresholdOne high value is not a diagnosis — seeChapter 26. STEP 4 · WILL THIS STONE PASS?Stone spontaneous passage rates bysizeSize drives the conversation. STEP 5 · HOW MUCH TIME DO I HAVE?TIME-CRITICALTorsion and priapism time windowsThe two clocks worth memorizing. STEP 6 · WHICH CATHETER?Adult catheter sizing and balloonfillRoutine vs. irrigation for clots. STEP 7 · HOW DO I READ THIS PSA OR IPSS?5-ARI effect on PSA, IPSS bands,and normal QmaxThe three interpretation aids. STEP 8 · IS THIS BLADDER DANGEROUS?Dangerous storage pressureThe number that predicts upper-tractloss. STEP 9 · TESTOSTERONE NUMBERSCastrate level, low-T threshold,and the hematocrit holdThree different testosterone numbersthat get confused. STEP 10 · OUR PRACTICE-SPECIFIC NUMBERSLOCAL POLICYThe practice's own thresholds andprotocol numbersThese are our practice positions, notgeneric values.

Select a box to open its teaching details.

Before using any value below

  • Every entry in this table is a rough reference — verify locally
  • Drug doses, hold times, and algorithms — especially in oncology, anticoagulation, and weight management — must be verified against up-to-date sources and the treating physician's plan before use
Appendix B — handy reference values

Value

  • ≥ 3 RBCs/HPF on microscopy — confirm; do not rely on the dipstick
Appendix B — handy reference values

Values

  • Normal PVR — generally < ~50–100 mL
  • Persistently > 300 mL is significant retention
Appendix B — handy reference values

Values

  • ≤ 5 mm — ~70–80%
  • 5–10 mm — ~40–50%
  • > 10 mm — unlikely
Appendix B — handy reference values
Time-critical

Torsion salvage window

  • Near 100% at < 6 h
  • ~70% at 6–12 h
  • ~20% at 12–24 h

Ischemic priapism

  • Emergency if > 4 hours
Appendix B — handy reference values

Values

  • 14–18 Fr routine
  • 20–24 Fr (3-way) for irrigation/clots
  • Balloon: sterile water, 10 mL
Appendix B — handy reference values

Values

  • 5-ARI effect on PSA — ≈ 50% reduction after 6–12 months (double the value to interpret)
  • IPSS bands — mild 0–7, moderate 8–19, severe 20–35
  • Normal Qmax — > 15 mL/s (needs a voided volume > 150 mL to be valid)
Appendix B — handy reference values

Value

  • Detrusor leak point pressure > 40 cm H2O → upper-tract risk

Pitfalls

  • This can be true in a completely asymptomatic patient (Chapter 25)
Appendix B — handy reference values

Values

  • Castrate testosterone — < 50 ng/dL (goal on ADT; many target < 20)
  • Low testosterone threshold — total T < ~300 ng/dL on TWO early-morning draws, plus symptoms
  • Testosterone therapy — hold for hematocrit > ~54%
Appendix B — handy reference values
Local policy

Our protocol

  • BPH procedure by size — UroLift < 50 g; PAE > 50 g. PCNL for stones > 4 cm
  • Every ADT patient: baseline DEXA + denosumab 60 mg SC q6 months. Every bone-mets patient: baseline DEXA + 120 mg SC every 12 weeks instead. All need dental clearance, calcium and vitamin D levels, and OTC calcium citrate + vitamin D3 gummies providing 1,200 mg calcium daily
  • Recurrent UTI (our practice protocol) — Hiprex 1 g BID (+ vitamin C 500 mg); vaginal estrogen (Estrace); reduced sugar; daily CIC irrigation with ~300 cc sterile/distilled water

Other dosing references

  • Semaglutide (Wegovy) titration — 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg weekly, ~4 weeks per step
  • Antibiotic prophylaxis timing — within 60 minutes of incision; a single pre-op dose for most cases

Pitfalls

  • Denosumab 60 mg q6 months and 120 mg every 12 weeks are different indications — verify before ordering (Chapter 23)
Appendix B — handy reference values

The practice's stated positions in benign urology. When a recommendation elsewhere conflicts with these, these are what this practice does.

What we do — benignThe practice's stated positions in benign urology. When a recommendation elsewhere conflicts with these, these are what this practice does. STEP 1 · CULTURELOCAL POLICYAsk anyone for help, always — andkeep care inside our four wallsHow the group works. STEP 2 · EVERY VISITLOCAL POLICYTake a FULL urologic history onevery patient, every timeRegardless of why they came in. STEP 3 · THE ASC BOUNDARYTIME-CRITICALThe septic obstructed stone goesto the HOSPITAL — never an ASCadd-onOur surgery centers aresame-day-discharge facilities. STEP 4 · RECURRENT UTILOCAL POLICYRecurrent UTI — antibiotics arenot the solutionPrevention protocol, and what wespecifically do not use. STEP 5 · BPH AND OABLOCAL POLICYBPH by gland size; beta-3 agonistsstrongly preferred for OABIncluding the procedures and drugs wedeliberately do not offer. STEP 6 · STONESLOCAL POLICYURS with thulium laser and vacuumaspiration in the ASC — every URSpatient is stentedPCNL reserved for stones > 4 cm. STEP 7 · EMERGENCIESTIME-CRITICALTorsion, priapism, and clothematuria — the practice's statedmovesThree positions worth knowing cold. STEP 8 · ED AND MEN'S HEALTHLOCAL POLICYThe ED ladder, and the TRTformulation orderIncluding the agent we do not use. STEP 9 · IC/BPS AND THE ABSOLUTE RULETIME-CRITICALHydroxyzine + Uro-MP first-line —and NEVER cystectomy for benigndiseaseThe single most important absolute inthis guide. STEP 10 · TECHNOLOGY MENULOCAL POLICYKnow the other our practicetechnologies before you refer outMost of this stays in-house.

Select a box to open its teaching details.

Local policy

Our position

  • One of the most collaborative groups in the country — ask anyone for help, always
  • We accept all major insurances, and we keep care inside our four walls
Appendix C — our practice positions
Local policy

Our position

  • Cover LUTS, hematuria, incontinence, sexual function, and PSA screening — every patient, every time
  • Patients do not volunteer these complaints

The reason

We are the urologists; if it walks in our door and leaves undiagnosed because nobody asked, that is on us (Chapter 1.4).

Appendix C — our practice positions
Time-critical

Our position

  • Our ASCs cannot take cases needing an overnight admission or an ICU bed
  • The septic patient with an obstructed, infected stone goes to the HOSPITAL for decompression plus inpatient sepsis care — never an ASC add-on (Chapter 2)
Appendix C — our practice positions
Local policy

Our protocol

  • Hiprex (+ vitamin C)
  • Vaginal estrogen (Estrace) for post-menopausal women
  • Reduced sugar
  • Daily CIC bladder irrigation (~300 cc sterile/distilled water)

What we do not use

  • We do not use D-mannose, cranberry, or probiotics
  • Reserve antibiotics for true symptomatic infection (Chapter 6)
Appendix C — our practice positions
Local policy

BPH procedures

  • UroLift for glands < 50 g
  • PAE for glands > 50 g — our gold standard for large glands
  • We do not offer Rezūm or GreenLight/PVP
  • Alpha-blockers are a short-term bridge (≤ ~1 year), not lifelong therapy

OAB

  • Beta-3 agonists strongly preferred
  • Anticholinergics used only very infrequently — we strongly advise against them (dementia, constipation, dry mouth, retention, falls)
  • InterStim offered early for definitive relief
Appendix C — our practice positions
Local policy

Our protocol

  • URS with thulium laser, Dornier single-use digital scopes, and vacuum aspiration in the ASC treats even massive stones
  • PCNL reserved for stones > 4 cm
  • Every URS patient is stented

Symptom control

  • Stent colic — Pyridium/Uro-MP + mirabegron
  • Non-narcotic pain — suzetrigine (Journavx)
Appendix C — our practice positions
Time-critical

Our protocol

  • Torsion — always gets a confirmatory Doppler ultrasound obtained in PARALLEL with mobilizing the OR
  • Priapism — come to the office immediately when it is open; if the office is closed, go to the ER. Treat it in the office or at the bedside: monitor, Dilaudid, penile block, 16-G angiocath, phenylephrine. It is almost never caused by a PDE5 inhibitor — think Trimix, sickle cell, cocaine
  • Gross hematuria with clots — start a 5-ARI immediately
Appendix C — our practice positions
Local policy

ED

  • We do not use intraurethral alprostadil (MUSE)
  • The ladder: PDE5 inhibitors → intracavernosal injection (Trimix) and VED → LISWT → penile prosthesis

Men's health

  • TRT formulation order — gel (1st, most physiologic), pellets (2nd), injections (last — the roller-coaster)
  • We avoid oral testosterone (cost/coverage)
  • Anastrozole to control estrogen when indicated
  • Enclomiphene when fertility must be preserved
Appendix C — our practice positions
Time-critical

IC/BPS

  • First-line oral therapy is HYDROXYZINE + URO-MP
  • We do NOT use Elmiron (pentosan polysulfate — irreversible pigmentary maculopathy)
  • We do NOT use cyclosporine (too toxic for benign disease)
  • Intravesical therapy is delivered ONLY at cystoscopy with hydrodistension (office or ASC) — no standalone instillation series (Chapter 27)

The absolute rule

  • NEVER perform a cystectomy with urinary diversion for BENIGN disease. The pain in IC/chronic pelvic pain is centrally sensitized — remove the bladder and the patient still hurts, but now with a lifelong diversion. Cystectomy is for cancer
Appendix C — our practice positions
Local policy

Our technologies

  • Bulkamid and ProACT for incontinence
  • LISWT and penile prosthesis for ED
  • Optilume for urethral stricture
  • Magnetic pelvic floor therapy
  • Tibial neuromodulation (AltaViva)
Appendix C — our practice positions

Practice positions in urologic oncology and bone health, then the guideline touchpoints behind them and the disclaimer that governs all of it.

What we do — oncology & sourcesPractice positions in urologic oncology and bone health, then the guideline touchpoints behind them and the disclaimer that governs all of it. STEP 2 · PROSTATE CANCERLOCAL POLICYWe do NOT use the DRE to evaluatefor prostate cancerPSA, PSA density, biomarkers, and mpMRIinstead. STEP 3 · BLADDER CANCERLOCAL POLICYThe intravesical menu — know whichagent maps to which disease stateTwo newer agents with very specificindications. STEP 4 · IMMUNOTHERAPYTIME-CRITICALAny new symptom on a checkpointinhibitor is an irAE until provenotherwiseTreat with STEROIDS, not symptomaticremedies. STEP 5 · BONE HEALTHLOCAL POLICYDenosumab biosimilar is our drugof choice — two doses, twoindicationsWe do not use bisphosphonates. STEP 6 · SOURCESFind the guideline behind therecommendationThe touchpoints this guide is built on. STEP 7 · BEFORE YOU ACTRead the disclaimer before usinganything in this appendixclinicallyThis is a quick reference fororientation and study.

Select a box to open its teaching details.

Local policy

Our position

  • We do NOT use the DRE — insensitive, misses anterior/transition-zone tumors, and deters screening
  • We use PSA, PSA density, validated biomarkers, and multiparametric MRI

Treatment and in-house services

  • Focal therapy menu — HIFU, PEF/pulsed-field, water-vapor
  • Barrigel spacer with radiation
  • In-house infusion suites — Keytruda, Opdivo, ipilimumab; subcutaneous Keytruda Qlex
  • Pharmacy dispensing — Orgovyx, Xtandi, Erleada, Nubeqa
Appendix C — our practice positions
Local policy

Our menu

  • ZUSDURI (mitomycin intravesical solution) — for recurrent LOW-grade intermediate-risk NMIBC; chemoablation without a TURBT
  • INLEXZO (gemcitabine intravesical system) — for BCG-UNRESPONSIVE high-risk NMIBC with CIS; an indwelling releasing device placed in the office
  • Also Adstiladrin, Anktiva + BCG, pembrolizumab, gem/doce
  • Jelmyto for low-grade upper-tract disease (Chapter 9)
Appendix C — our practice positions
Time-critical

Our position

  • We run a lot of Keytruda, Opdivo, and Yervoy in-house
  • Any new symptom on a checkpoint inhibitor is an immune-related adverse event until proven otherwise

The "-itis" list

  • Colitis
  • Thyroiditis
  • Hepatitis
  • Pneumonitis
  • Hypophysitis
  • Nephritis
  • Myocarditis

Pitfalls

  • Treat with STEROIDS, not symptomatic remedies (Chapter 20.10)
Appendix C — our practice positions
Local policy

Our protocol

  • Denosumab (biosimilar) is our drug of choice
  • Every ADT patient: baseline DEXA + 60 mg q6 months
  • Every patient with bone metastases: baseline DEXA + 120 mg every 12 weeks instead
  • Do not give both regimens
  • All need dental clearance, calcium and vitamin D levels, and OTC calcium citrate + vitamin D3 gummies providing 1,200 mg calcium daily
  • If denosumab is stopped, transition to zoledronic acid (Zometa)
  • Bisphosphonates are not routine first-line therapy; Zometa is required when transitioning off denosumab

The exception

  • An ANABOLIC (romosozumab, teriparatide, abaloparatide) first-line for women with severe osteoporosis — T-score ≤ −3.0, recent or multiple fragility fractures — always followed by denosumab to lock in the gains (Chapter 23.4)

Pitfalls

  • Confusing the 60 mg q6 months and 120 mg every 12 weeks regimens is a real and dangerous error
Appendix C — our practice positions

Guidelines

  • AUA/SUFU Microhematuria (2025)
  • AUA BPH/LUTS (2026)
  • AUA/SUFU Idiopathic Overactive Bladder (2024)
  • AUA Urologic Procedures and Antimicrobial Prophylaxis Best Practice Statement
  • AUA/SUFU Adult Urodynamics
  • AUA IC/BPS Guideline

Oncology and labeling

  • NCCN Prostate Cancer (2026) — mCSPC intensification and triplet therapy
  • SNMMI/NCCN PSMA PET appropriate-use criteria
  • FDA labeling for Lu-177 PSMA-617 (Pluvicto), PARP-inhibitor combinations, denosumab, and semaglutide
Appendix D — guideline and evidence touchpoints

What this guide is

An educational quick reference for orientation and study, tailored to Central Ohio Urology Group's practice preferences.

What it is not

  • Not a substitute for clinical judgment, direct supervision, institutional protocols, or the full text of current guidelines
  • Drug doses, hold times, and treatment algorithms — especially in oncology, anticoagulation, and weight management — must be verified against up-to-date sources and the treating physician's plan before use
  • Guidelines and approvals evolve — confirm the latest AUA/SUFU/NCCN/FDA recommendations
  • Procedural descriptions are a supplement to supervised hands-on training, never a substitute for it
Appendix — important disclaimer

Suggest a change

Reviewed before anything changes

Something wrong, out of date, or missing? Say so here. Your note is logged against this chapter and this location. No account needed.

PreviousPerioperative Medications: Anticoagulation and Antibiotic Prophylaxis NextWhat’s New in Urology